July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Are Anti-angiogenics (Bevacizumab) Intravitreal Injections as Effective as Intravitreal Triamcinolone Acetonide Injections for the Management of Persistent Non-infectious Uveitic Cystoid Macular Edema?
Author Affiliations & Notes
  • J Fernando Arevalo
    Retina Division, The Wilmer Eye Institute-Johns Hopkins University, Baltimore, Maryland, United States
  • Andres F Lasave
    Retina and Vitreous Service, Clinica Privada de Ojos, Mar del Plata, Argentina
  • Bernardo Ariel Schlaen
    Hospital Universitario Austral, Servicio de Oftalmología, Derqui-Pilar, Buenos Aires, Argentina
  • David Zeballos
    Clinica de Ojos, Cuenca, Ecuador
  • Manuel Díaz-Llopis
    Consorcio Hospital, General Universitario de Valencia, Valencia, Spain
  • Cristobal Avelino Couto
    Uveitis Clinics, Department of Ophthalmology, Universidad de Buenos Aires, Buenos Aires, Argentina
  • Wael El-Haig
    Ophthalmology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  • Footnotes
    Commercial Relationships   J Fernando Arevalo, None; Andres Lasave, None; Bernardo Schlaen, None; David Zeballos, None; Manuel Díaz-Llopis, None; Cristobal Couto, None; Wael El-Haig, None
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 420. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Fernando Arevalo, Andres F Lasave, Bernardo Ariel Schlaen, David Zeballos, Manuel Díaz-Llopis, Cristobal Avelino Couto, Wael El-Haig; Are Anti-angiogenics (Bevacizumab) Intravitreal Injections as Effective as Intravitreal Triamcinolone Acetonide Injections for the Management of Persistent Non-infectious Uveitic Cystoid Macular Edema? . Invest. Ophthalmol. Vis. Sci. 2018;59(9):420.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for the treatment of persistent non-infectious uveitic cystoid macular edema (CME).
<div class="grammarly-disable-indicator"> </div>

Methods : Interventional retrospective comparative case series. Thirty-seven consecutive patients (44 eyes) were included. Patients received repeated injections either 1.25 mg of IVB (20 eyes) or 4 mg of IVT (24 eyes). Patients were included if uveitis was completely controlled, and CME was unresponsive to medical treatment in one or both eyes.
<div class="grammarly-disable-indicator"> </div>

Results : In the IVB group, baseline best-corrected visual acuity (BCVA) was logMAR 1, and improved to 0.8 (p=0.002) at 24 months. In the IVT group, baseline BCVA was logMAR of 1.1 and improved to 0.6 at 24 months (p= 0.001). At 24-month, central macular thickness (CMT) in the IVB group improved from 399.2 µm to 333.7 µm (p< 0.0009) and from 464.4 µm to 316.5 µm (p=0.044) in the IVT group. There was a significant increase in IOP in the IVT group compared with the IVB group at all time points of the study.
<div class="grammarly-disable-indicator"> </div>

Conclusions : Repeated injections with IVT improve BCVA as effectively as repeated injections with IVB in the long-term management of persistent uveitic CME .
<div class="grammarly-disable-indicator"> </div>

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×